Q3 Earnings Forecast for TNYA Issued By HC Wainwright

Key Points

• HC Wainwright expects Tenaya Therapeutics to report a Q3 2026 loss of $0.09 per share, with a projected Q4 loss of $0.10 per share. The consensus full-year estimate is a loss of $0.42 per share.
• Tenaya’s latest quarterly results matched expectations at a loss of $0.09 per share, but revenue of $0.23 million fell far short of the $7.50 million analyst consensus.
• The stock opened at $0.73, down 7.5%, and has a “Moderate Buy” consensus rating with an average price target of $4.00. Institutional investors own approximately 90.54% of the company.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for Tenaya Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.09) for the quarter. The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Tenaya Therapeutics' Q4 2026 earnings at ($0.10) EPS.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.09). The business had revenue of $0.23 million for the quarter, compared to analysts' expectations of $7.50 million.

Several other analysts also recently weighed in on the stock. Weiss Ratings raised shares of Tenaya Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 28th. Wall Street Zen cut shares of Tenaya Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Tenaya Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $4.00.

Tenaya Therapeutics Stock Down 7.5%

Shares of Tenaya Therapeutics stock opened at $0.73 on Friday. The company has a 50 day moving average price of $0.77 and a 200 day moving average price of $0.76. The firm has a market capitalization of $157.50 million, a P/E ratio of -1.37 and a beta of 2.83. Tenaya Therapeutics has a 52 week low of $0.53 and a 52 week high of $2.35.

Institutional Investors Weigh In On Tenaya Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Integrity Wealth Solutions LLC acquired a new position in Tenaya Therapeutics in the 1st quarter worth approximately $27,000. Scientech Research LLC acquired a new position in Tenaya Therapeutics during the third quarter valued at $27,000. Comerica Bank acquired a new position in Tenaya Therapeutics during the first quarter valued at $50,000. Cerity Partners LLC boosted its holdings in Tenaya Therapeutics by 403.5% in the second quarter. Cerity Partners LLC now owns 110,336 shares of the company's stock valued at $67,000 after purchasing an additional 88,424 shares during the last quarter. Finally, Corient Private Wealth LLC acquired a new stake in Tenaya Therapeutics during the 4th quarter worth about $72,000. Institutional investors and hedge funds own 90.54% of the company's stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source